NEW YORK (Reuters) - Fitness experts are shining a new light on group classes from Zumba to yoga because they believe the right lighting can transform the four walls of a fitness studio from a dance party to a ...
DUBLIN (Reuters) - Elan announced its second major drug deal inside a week on Monday and said it would buy back more shares as it continues to bat against a $5.7 billion takeover bid from U.S. investor Royalty ...
NEW YORK (Reuters Health) - Boys who are diagnosed with attention-deficit/hyperactivity disorder (ADHD) in elementary school are more likely to grow up to be obese adults than those who don't have the condition, a new ...
NEW YORK (Reuters Health) - A newer version of the whooping cough vaccine doesn't protect kids as well as the original, which was phased out in the 1990s because of safety concerns, according to a new study.
During a ...
JAKARTA (Reuters) - When a sick Indonesian baby died after 10 hospitals in Jakarta turned her family away in February, critics blamed a pilot health insurance scheme that had overwhelmed the city's public ...
The companies said the deal had an enterprise value, including debt, of $8.5 billion.
The move comes as Actavis has spurned approaches from Canadian pharmaceutical company Valeant Pharmaceuticals International Inc and ...
(Reuters) - Merck & Co's experimental insomnia drug suvorexant appears generally effective, according to reviewers at the U.S. Food and Drug Administration, but they questioned the company's proposed dosing ...
Shares of the company were down 28 percent at $4.85 before the bell.
The company said it would shut down all activities related to the drug, arbaclofen placarbil, and planned to provide an update on the impact of the ...
In a disease outbreak update issued from its Geneva headquarters, the WHO said the latest patient is an 81-year-old woman with multiple medical conditions. She became ill on April 28 and is in a critical but stable ...
Lundbeck said in a statement that the trial showed safety levels consistent with previously completed studies at lower doses.
Lundbeck and Takeda submitted vortioxetine, also known as Brintellix, for regulatory ...
